Yutaka Oji

Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

Vera Bril, Artur Drużdż, Julian Großkreutz et al. · The Lancet Neurology · 2023 · 227 citations

Clinical Trials, Generalised Myasthenia Gravis, Pharmacotherapy +3

Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson’s disease

Shinji Saiki, Taku Hatano, Motoki Fujimaki et al. · Scientific Reports · 2017 · 140 citations · Full text

A metabolic profile of polyamines in parkinson disease: A promising biomarker

Shinji Saiki, Yukiko Sasazawa, Motoki Fujimaki et al. · Annals of Neurology · 2019 · 120 citations · Full text

Variants in saposin D domain of prosaposin gene linked to Parkinson’s disease

Yutaka Oji, Taku Hatano, Shin-Ichi Ueno et al. · Brain · 2020 · 111 citations · Full text

Genetics, Neurochemical Biomarkers, Lysosomal Storage Disorders +17

Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease

Motoki Fujimaki, Shinji Saiki, Yuanzhe Li et al. · Neurology · 2018 · 103 citations · Full text